Passage Bio Stock Today
| PASG Stock | USD 10.99 1.08 8.95% |
PerformanceFair
| Odds Of DistressStrong
|
Passage Bio is trading at 10.99 as of the 4th of February 2026. This is a 8.95 percent decrease since the beginning of the trading day. The stock's lowest day price was 10.78. Passage Bio has a very high chance of experiencing financial distress in the next few years of operation. However, it had a very fair returns during the last 90 days. The performance scores are derived for the period starting the 6th of November 2025 and ending today, the 4th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of February 2020 | Category Healthcare | Classification Health Care |
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Passage Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 3.18 M outstanding shares of which 15.14 K shares are at this time shorted by private and institutional investors with about 0.18 trading days to cover. More on Passage Bio
Moving against Passage Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Passage Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | William MD | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsPassage Bio utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Passage Bio's leverage profile, showing how much of Passage Bio's resources are funded through borrowing.
| |||||
Passage Bio (PASG) is traded on NASDAQ Exchange in USA and employs 60 people. Passage Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 34.93 M. Passage Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.18 M outstanding shares of which 15.14 K shares are at this time shorted by private and institutional investors with about 0.18 trading days to cover.
Passage Bio currently holds about 239.25 M in cash with (47.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39.
Check Passage Bio Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Passage Bio is $34.93 Million. Over half of Passage Bio's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Passage Ownership Details
Passage Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2025-03-31 | 156.8 K | |
| Rbf Llc | 2025-03-31 | 142.8 K | |
| Millennium Management Llc | 2025-03-31 | 136.2 K | |
| Northern Trust Corp | 2025-03-31 | 112 K | |
| Simplex Trading, Llc | 2025-03-31 | 82.3 K | |
| Two Sigma Investments Llc | 2025-03-31 | 47 K | |
| Xtx Topco Ltd | 2025-03-31 | 45.4 K | |
| Ubs Group Ag | 2025-03-31 | 14.5 K | |
| Mariner Wealth Advisors Llc | 2025-03-31 | 11.9 K | |
| Orbimed Advisors, Llc | 2025-03-31 | 7 M | |
| Vestal Point Capital Lp | 2025-03-31 | 6.1 M |
Passage Bio Historical Income Statement
Passage Stock Against Markets
Passage Bio Corporate Management
| Sue Browne | Senior Development | Profile | |
| Simona King | CFO Sec | Profile | |
| JD Esq | General Secretary | Profile | |
| Gregory Fuest | Vice Marketing | Profile | |
| MSc MBA | Chief Officer | Profile | |
| Kathleen Borthwick | Principal Finance | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Can Biotechnology industry sustain growth momentum? Does Passage have expansion opportunities? Factors like these will boost the valuation of Passage Bio. Anticipated expansion of Passage directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Passage Bio demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Investors evaluate Passage Bio using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Passage Bio's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause Passage Bio's market price to deviate significantly from intrinsic value.
It's important to distinguish between Passage Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Passage Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Passage Bio's market price signifies the transaction level at which participants voluntarily complete trades.